DCEBIO

CAS No. 60563-36-2

DCEBIO( —— )

Catalog No. M26145 CAS No. 60563-36-2

DCEBIO stimulates the secretion of Cl- through the activation of the hIK1 K + channel and the activation of the apical Cl- conductance.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 67 In Stock
5MG 61 In Stock
10MG 93 In Stock
25MG 188 In Stock
50MG 305 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    DCEBIO
  • Note
    Research use only, not for human use.
  • Brief Description
    DCEBIO stimulates the secretion of Cl- through the activation of the hIK1 K + channel and the activation of the apical Cl- conductance.
  • Description
    DCEBIO stimulates the secretion of Cl- through the activation of the hIK1 K + channel and the activation of the apical Cl- conductance. DCEBIO is a derivative of 1-EBIO and a very strong activator of Cl- secretion by T84 colon cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Potassium Channel
  • Recptor
    Endogenous Metabolite
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    60563-36-2
  • Formula Weight
    231.08
  • Molecular Formula
    C9H8Cl2N2O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (216.38 mM)
  • SMILES
    CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Lee Y, Jung SW, Park SH, Yoo JW, Park J. Synthesis of Tungsten-Doped Vanadium Dioxide Using a Modified Polyol Method Involving 1-Dodecanol. Materials (Basel). 2020 Nov 27;13(23):5384. doi: 10.3390/ma13235384. PMID: 33260827; PMCID: PMC7730659.
molnova catalog
related products
  • VU590

    VU590 is a potent and moderately selective inhibitor of extrarenal medullary potassium ROMK (Kir1.1) that also inhibits Kir7.1 and modulates uterine myometrial contractility and melanocortin signalling.

  • BMS-813160

    BMS-813160 is the first dual?CCR2/CCR5?antagonist to enter Clinical development for cardiovascular.

  • ML418

    ML418 is a potent, selective and CNS penetrating Kir7.1 potassium channel blocker (IC50 = 310 nM), and also potently inhibits Kir6.2/SUR1.